Croda’s Post

Today we have announced our first half results for 2024, with Group performance in line with expectations. The Group returned to year-on-year growth in the second quarter, helped by more stable market conditions, price discipline and continued operational progress.   We’ve seen continued momentum in higher growth areas where we have focused recent investment, testament to our strategy to realign the portfolio towards the megatrends shaping our industry.   Our strong relationships with local and regional customers are driving growth as they innovate and grow quickly. And with growing customer pipelines across biologics, vaccines and nucleic acid-based drugs, our strategic focus areas in Pharma will accelerate Croda’s future growth.   I want to thank all our people for their commitment and hard work so far this year; we are emerging from a tough environment more focused on and more exposed to fast growth markets and we are ready for another period of exciting, innovation-led growth. https://lnkd.in/db6yRaFS